It’s only fair to share… Dapolsertib CAS 1616359-00-2 MF C15H18Br2N4O MW 446.14 g/mol 5,6-dibromo-4-nitro-2-piperidin-4-yl-1-propan-2-ylbenzimidazole 5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzimidazoleserine/ threonine kinase inhibitor, antineoplastic Ryvu Therapeutics SA, MEN1703, SEL24-B489 Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed …